Three Lions reports unaudited balance sheet
Three Lions Acquisition Corp. filed unaudited financial statements as of late 2026, managing trust account assets exceeding $100 million. This regulatory filing had no material imp…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Three Lions Acquisition Corp. filed unaudited financial statements as of late 2026, managing trust account assets exceeding $100 million. This regulatory filing had no material imp…
Disc Medicine reports its DISC-3405 treatment successfully reduces phlebotomy needs for polycythemia vera patients at the SOHO conference. In its market-perceived most strategic as…
Prelude Therapeutics announced FDA clearance for a Phase 1 study of oral degrader PRT13722 in HR+ breast cancer, with anticipated enrollment starting in Q4 2026. This regulatory mi…
EyePoint expanded analysis of its LUGANO Phase 3 trial for DURAVYU in wet AMD, citing potential practice-changing data and renewed confidence just months before an anticipated FDA …
Stewards, Inc. received Nasdaq approval to move its stock from OTC to Nasdaq, trading under the symbol SWRD starting Sept. 10. This milestone is expected to increase visibility amo…
Canadian Derivatives Clearing Corporation filed an exhibit listing the underlying interests for options listed on the Montreal Exchange and sold in the United States, as required b…
Korn Ferry filed an exhibit allowing Ernst & Young to incorporate by reference the firm's prior reports, which remains effective through the company's Form 8-K.
Andretti Acquisition II amends its charter to extend the deadline for completing a business combination to 36 months. This amendment provides the SPAC with additional time to explo…
FitLife Brands disclosed in an exhibit that a significant deficiency was discovered in its internal control over financial reporting, resulting in an audit extension for fiscal yea…
Advasa provided clarifications regarding its direct listing, share resale prospectus, and ownership status of its largest shareholder, while confirming no recent sales by the share…
Gossamer Bio announced a 1-for-80 reverse stock split to regain Nasdaq listing compliance. The split became effective on September 11, reducing the authorized share count to 50 mil…
Intelligent Bio Solutions Inc. submitted a 510(k) package to the FDA for its Intelligent Fingerprinting Drug Screening System, targeting U.S. market clearance for codeine detection…
The company received confirmation from Nasdaq that it has regained compliance with the minimum bid price and rights and warrants rules, canceling the previously scheduled hearing. …
The independent Safety Monitoring Committee recommended Serina Therapeutics advance its SER-252 study to Cohort 2 following blinded positive safety and tolerability data in advance…
Incannex Healthcare provides a corporate update, reporting patient dosing in the DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea and the grant of a U.S. composition pa…
Apnimed reported second quarter 2026 financial results and is advancing commercial readiness for Oxnimbi following FDA acceptance of the NDA and completion of a successful IPO.
Lightbridge Corp has been selected for the DOE Launch Pad INL Program, enabling an accelerated pathway for the commercial deployment of its Lightbridge Fuel through a new two-prong…
In a randomized Phase 2 head and neck cancer study, INBRX-106 plus pembrolizumab achieved a 48.3% confirmed objective response rate, significantly outperforming pembrolizumab monot…
Nevada corporation La Rosa Holdings filed an amendment to its articles of incorporation, as authorized by stockholders holding at least a majority of voting power.
Veru will proceed with a Phase 2 trial for new metastatic pancreatic cancer research showing its drug overcomes resistance to Revolution Medicines' daraxonrasib, signaling a potent…